Skip to main content
Premium Trial:

Request an Annual Quote

Roche, Exiqon Reach Co-Marketing Deal

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Roche Applied Science and Exiqon today announced a joint marketing agreement covering Roche's RealTime ready assays and Exiqon's miRCURY LNA Universal RT microRNA pPCR system.

Financial terms were not disclosed.

Roche's RealTime assays are based on Exiqon's Universal ProbeLibrary technology and offer "maximized testing efficiency," Exiqon said in a statement. In 2008, the two firms inked a deal under which Roche was given co-exclusive rights to use Exiqon's Universal ProbeLibrary of LNA oligonucleotides to develop and manufacture its RealTime ready qPCR assays.

Exiqon said today that its LNA-enhanced PCR primers have "exceptional" sensitivity and specificity, "enabling accurate quantification of very low amounts of microRNA obtained from difficult samples," including frozen formalin paraffin-embedded tissue, serum, plasma, and laser capture microscopy.

The Scan

Back as Director

A court has reinstated Nicole Boivin as director of the Max Planck Institute for the Science of Human History, Science reports.

Research, But Implementation?

Francis Collins reflects on his years as the director of the US National Institutes of Health with NPR.

For the False Negatives

The Guardian writes that the UK Health Security Agency is considering legal action against the lab that reported thousands of false negative COVID-19 test results.

Genome Biology Papers Present Epigenetics Benchmarking Resource, Genomic Architecture Maps of Peanuts, More

In Genome Biology this week: DNA methylation data for seven reference cell lines, three-dimensional genome architecture maps of peanut lines, and more.